Joseph H A Vissers
Overview
Explore the profile of Joseph H A Vissers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
847
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Long G, Shklovskaya E, Satgunaseelan L, Mao Y, Pires da Silva I, Perry K, et al.
Nat Med
. 2025 Feb;
PMID: 40016450
Glioblastoma (GBM) is an aggressive primary adult brain tumor that rapidly recurs after standard-of-care treatments, including surgery, chemotherapy and radiotherapy. While immune checkpoint inhibitor therapies have transformed outcomes in many...
2.
Mitchell K, Vissers J, Pojer J, Brooks E, Hilmi A, Papenfuss A, et al.
Curr Biol
. 2024 Aug;
34(17):3966-3982.e7.
PMID: 39146938
Epithelial organs maintain their integrity and prevent tumor initiation by actively removing defective cells, such as those that have lost apicobasal polarity. Here, we identify how transcription factors of two...
3.
Andrew E, Lewin J, Desai J, Orme L, Hamilton A, Bae S, et al.
J Pers Med
. 2024 Feb;
14(2).
PMID: 38392562
Sarcomas are a heterogenous group of tumours that commonly carry poor prognosis with limited therapeutic options. Adolescents and young adults (AYAs) with sarcoma are a unique and understudied patient population...
4.
Abdelmogod A, Papadopoulos L, Riordan S, Wong M, Weltman M, Lim R, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686662
Background: Epithelioid haemangioendothelioma (EHE) is an ultra-rare malignant vascular tumour with a prevalence of 1 per 1,000,000. It is typically molecularly characterised by a gene fusion in approximately 90% of...
5.
Dall G, Vandenberg C, Nesic K, Ratnayake G, Zhu W, Vissers J, et al.
J Exp Clin Cancer Res
. 2023 May;
42(1):112.
PMID: 37143137
Background: Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations in the homologous recombination (HR) DNA...
6.
Aranza S, Roydhouse C, Mitchell C, Vissers J, Lo W, Grimmond S, et al.
Pathology
. 2022 Jun;
55(4):568-571.
PMID: 35691724
No abstract available.
7.
Mweempwa A, Xu H, Vissers J, Tothill R, Pattison A, Fellowes A, et al.
JCO Precis Oncol
. 2022 Jan;
5:1160-1165.
PMID: 34994633
No abstract available.
8.
The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer
Vervoort S, Welsh S, Devlin J, Barbieri E, Knight D, Offley S, et al.
Cell
. 2021 May;
184(12):3143-3162.e32.
PMID: 34004147
Gene expression by RNA polymerase II (RNAPII) is tightly controlled by cyclin-dependent kinases (CDKs) at discrete checkpoints during the transcription cycle. The pausing checkpoint following transcription initiation is primarily controlled...
9.
Sutherland K, Vissers J
J Thorac Oncol
. 2020 Jun;
15(7):1106-1109.
PMID: 32593443
No abstract available.
10.
Kulkarni A, Chang M, Vissers J, Dey A, Harvey K
Trends Cancer
. 2020 May;
6(9):781-796.
PMID: 32446746
The Hippo pathway regulates myriad biological processes in diverse species and is a key cancer signaling network in humans. Although Hippo has been linked to multiple aspects of cancer, its...